首页> 外文OA文献 >High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

【2h】

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

机译：在发生伊马替尼（sTI571）耐药的慢性粒细胞白血病或ph阳性急性淋巴细胞白血病患者中，BCR / aBL腺苷三磷酸结合区内的点突变频率高

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

著录项

作者
Branford S.; Rudzki Z.; Walsh S.; Grigg A.; Arthur C.; Taylor K.; Herrmann R.; Lynch K.; Hughes T.;
展开▼
作者单位

展开▼
年度 2002
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib | Haematologica [J] . Paul La Rosée, Susanne Holm-Eriksen, Heiko Konig, Haematologica . 2008,第5期

机译：磷酸CRKL监测用于评估尼洛替尼治疗的伊马替尼耐药的慢性粒细胞白血病或Ph +急性淋巴细胞白血病患者的BCR-ABL活性|血液学
2. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. [J] . Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Cancer: A Journal of the American Cancer Society . 2014,第7期

机译：从伊马替尼到第二代酪氨酸激酶抑制剂时代的费城染色体阳性急性淋巴细胞白血病的耐药性和BCR-ABL激酶结构域突变：主要变化在于突变类型，但不涉及突变的发生频率。
3. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. [J] . Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Cancer: A Journal of the American Cancer Society . 2014,第7期

机译：从伊马替尼到第二代酪氨酸激酶抑制剂时代的费城染色体阳性急性淋巴细胞白血病的耐药性和BCR-ABL激酶结构域突变：主要变化在于突变类型，但不涉及突变的发生频率。
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. New strategies for targeted chronic myeloid leukemia therapy: Disrupting BCR-ABL1 dimerization and secondary leukemia-specific pathways [D] . Woessner, David W. 2013

机译：针对性慢性粒细胞白血病治疗的新策略：破坏BCR-ABL1二聚化和继发性白血病特异性途径
6. Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era [O] . Zafar Iqbal, Aamer Aleem, Mudassar Iqbal, 2010

机译：新诊断的慢性阶段性骨髓性白血病患者CD34 +细胞中先前存在的BCR-ABL激酶结构域突变的敏感检测与伊马替尼耐药相关：在伊马替尼时代后的意义
7. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia [O] . Shah Neil P., Nicoll John M., Nagar Bhushan, 2002

机译：多个BCR-ABL激酶结构域突变在慢性期和胚芽危机性慢性粒细胞白血病中赋予酪氨酸激酶抑制剂伊马替尼（STI571）多克隆耐药性

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅